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C hol esterol , fatty acid, and sphingolipid synthesis are re-
quired for barrier homeostasis, as demonstrated by studies 
w h ere synthesis of these species is stimulated in parallel with 
barrier repair. Moreover, blockade of synthesis of these lipids 
w ith inhibitors of two of the rate-l imiting enzymes, 
H M GCoA reductase (Iovas tatin , flu vastatin) and serine pal-
m itoyl transferase (,8-ch loroalanine), alters th e kinetics of 
barrier repair. Whereas these studies demonstrated a require-
ment for these lipids individually, we as ked here whether 
these lipids are requi red in either an additive or cooperative 
fas hion. W e applied each class of inhibitor alone or the two 
classes of inhibitors together to ace tone-treated skin, or each 
class separate ly to essential fatty acid deficient murine skin. 
W h en fluvastatin or fJ-chloroalanine was applied individu-
ally to acetone-treated skin , each caused a delay in the early or 
late stages of barrier recovery, respectively (assessed as trans-
T he epidermal permeability barrier resides in the stra-tum corneum , wh ere it is loca lized to th e intercellular spaces [1 ,2], and organized into membrane mu lti-layers w ith a charac teristic lamellar repeat structure [3,4]. Alth ough th e molecular architecture of their 
constituent lipids is not known, th e intercell ular lamellae contain 
pred ominantly ceramides, cho lestero l, and free fa tty ac ids [5 - 7] . 
Because of th eir weight contribution (= 40%), amphipathic ye t 
hig hly hydroph obic composition [8 ,9], and enrichment in the es-
sen t ia l fatty ac id, lino leatc [10 - 12]' ceramides have been pin-
pointed as th e lipid species most critica l fo r barrier function [13] . 
Yet , reeent metabo lic studies have demonstrated that cho lesterol 
[14- 16], fa tty acid [1 5], and sphingoli pid sy nthesis [17,1 8] are reg-
ulated by barrier req uirements, and that each of these lipids may be 
requi red for barrier homeostas is in murine epidermis. Moreover, 
essential fatty acid defi cient (EFAO) mice also displ ay accelerated 
choles terol [1 9,20]' fa tty ac id [1 5], and sphingolipid [17] synth esis 
in relation to th eir barrier abnormality. 
T o explore more definiti ve ly the ro le o f epidermal lipid sy nthesis 
and specific lipids in the barrier, we have employed lipid sy nthesis 
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epidermal water loss). However, when applied together they 
caused no furth er worsening at the early time point and a 
paradoxica l improvement at the later time points. This im-
provement correlated with an accelera ted return of sphingo-
.Iipids, w hich was perhaps due to a global stimulation ofl ipid 
synthesis induced by HMGCoA reductase inhibitors. In es-
sentia l fatty acid defici ent anima ls, inhibition of HMGCoA 
reductase caused drastic worsening of both clinical appear-
ance and barrier function , but ,8-chloroalanine caused a para-
doxical improvement, which correlated with a significant 
reduction in epidermal sphingolipids. T hese results are 
consistent with a requirement for both cholesterol and 
sphingolipids for barrier homeostasis, and also with the sug-
gestion that both of these lipids must be present (with free 
fatty acids) for optimal barrier function. ] In llest DermatoL 
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inhibitors. T opical applications of competitive inhibitors of 3-hy-
droxy-3-methyl-g lutaryl coenzyme A (HMGCoA) reductase, the 
rate- limiting enzyme of cho lesterol synthesis, to ace tone- treated 
skin caused a significan t delay in barrier recovery [21]. Li kewise, 
fJ-chloroalanine (B C A), an inhibi to r o f serine palmitoy l transferase, 
the rate-limiting enzyme of epidermal sphingolipid synthesis, also 
delayed barrier recovery in the acetone mode l, but the kinetics were 
different [1 8]. Although HMGCoA reductase inhibitors caused a 
delay in early barrier repair, inhibition of sphingolipid synthesis 
delayed barrier repai r onl y after 12 h. 
Whereas these earlier studies demonstrated the requirement for 
the synthesis o f ind.ividual lipids, we now asked whether the simul-
taneous inhibition of two lipid synth esis path ways w ould provoke a 
further abnormality in barrier recovery. T o address this issue, we 
applied the cho les terol and sphingolipid synthesis inhibitors not 
onl y alone, but also toge ther to acetone-trea ted mice. In addition, 
we asked w hether either class of inhibitor would provoke a furth er 
worsening of the barrier in EFAD animals, who possess a pre-exist-
in g deficiency of the essential free fa tty acid , lino leic acid. W hereas 
w e hypothesized that such inhibito rs would greatly w orsen barrier 
fun ction, in fac t in both models we found th at certain combi na tions 
o f treatment instead caused a paradoxical improvement in barrier 
function. 
MATERIALS AND METHODS 
Materials Male hairless mice (Hr/ Hr) , 8- 12 wccks old, wcre purchascd 
from Simonsen Laboratories (Gilroy , CAl, and fcd Purina mouse diet and 
water ad Iibilll lll . EFAD status was attaincd by maintai ning hairless micc on 
an EFAD diet [22] fo r 7 - 8 weeks until transcpidermal water loss (TEW L) 
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levels exceeded 1.0 mg/cm2/ h (see below). Acetone and propylene glycol 
were purchased from Fisher Scientific (Fairlawn, NJ). f1-chloroalanine was 
purchased from Sigma Chemical Co. (St. Louis, MO). Ruthenium tetroxide 
and osmium tetroxide were purchased from Polysciences, Inc. (Warrington, 
PAl. Lovastat in was kindly provided by Dr. A. Alberts of Merck, Sharp, and 
Dohme, Inc. (Rahway, NJ). Another HMGCoA reductase inhibitor, 
XU62-320 (f1uindostatin, f1uvastatin), was kindly provided by Dr. A. Stutz, 
Sandoz Research Institute, Vienna, Austria. 
Experimental Protocols In the first experimental model, f1uvastatin 
(400 Ilg), BCA (400 Ilg) alone, the combination of the two drugs, or vehicle 
(propylene glycol: ethanol; 7: 3 vol) alone was applied after perturbation of 
the barrier with acetone as described previously [15]. The barner was 
disrupted to a TEWL between 2 and 6 mg/cm2/ h (normal < 0.1 mg/cm2/ 
h). TEWL was measured with an electrolytic water analyzer (MEECO, 
Warrington, PAl at different time points after drug application [1 4-16,22]. 
In the second experimental model , either BCA (400 jlg), f1uvastatin 
(400 Ilg), or lovastatin (1 mg) was applied daily to one flank ofEFAD mice 
for up to 8 d. The vehicle-treated, EFAD mice served as the control. TEWL 
readings were taken from treated sides daily, or every other day, immediately 
prior to the nex t drug or vehicle application. Data for EFAD animals are 
presented as mean ± SEM of the TEWL measurements. In the acetone 
experiments, data are expressed as mean ± SEM of the percent change from 
the initial reading because the extent of barrier disruption varies from animal 
to an imal, and to compare large groups of animals it is necessary to normalize 
the data to account for these variations in barrier perturbation. Regardless of 
the initial TEWL value, the rate of recovery is similar, and expressed as 
percent barrier recovery. 
Lipid Extraction and Chromatography Eighteen hours after acetone 
with or without drug treatment (see above), epidermal sheets were obtained 
from hairless mouse skin by exposure to dry heat (60 ·C for 60 seconds), and 
stratum corneum was obtained by trypsinization [7]. Lipids were extracted 
from the stratum corneum sheets as described previously [6,7], dried, 
weighed, and stored at -70· C in chloroform until use. In addition, epider-
mis was collected from EFAD mice on day 6 after drug treatment by heat 
separation [14 - 16]. Epidermal lipids from both drug and vehicle-treated 
EFAD mice were fractionated and quantitated by high-performance thin-
layer chromatography (HPTLC) followed by charring and scanning densi-
tometry [23], as recently modified [17]. Briefly, 2 and 6 Ilg lipid were applied 
ontO thin-layer chromatography plates for neutral lipid analysis , and 8 and 
20llg, for sphingolipid analysis. Next, 0.2 to 1.0 Ilg each of the standard 
lipids were applied to the plates to generate standard curves. Sphingolipids 
were developed to 20 mm in chloroform: methanol: acetone: acetic acid 
(76: 20: 4 : I , v.ol) , to 50 111m in ch loroform: methanol: acetone (80: 10: 10, 
vol), and to the top in chloroform: ethyl acetate: diethyl ether: methanol 
(76: 20: 6.2, vol). Neutral lipids were fractionated by developing in petro-
leum ether : diethyl ether: acetic acid (80: 20 : 1, vol) to 40, 60, and 80 mm. 
The plates were scanned with a variable wavelength scanning densitometer 
(Camag) and the lipid fractions quantitated by comparison to known stan-
dards run simultaneously in duplicate for each fractio n. Integration was 
performed using CATS II software (Camag). 
Histochemistry Skin biopsies were taken from f1uvastatin, BCA, and 
vehicle-treated EFAD mouse skin on day 6. Samples were snap-frozen in 
I iquid nitrogen, sectioned at 4 11m, and stained with nile red for the depiction 
of lipid distribution in skin [24]. Sections were visualized with an Ortholux 
II microscope, equipped for epifluorescence (E. Leitz, Inc., Rockleigh, NJ). 
Electron Microscopy Eighteen hours after app lications of f1uvastatin, 
BCA, the two inhibitors together, or vehicle, samples were taken from 
treated and control areas for electron microscopy, minced to 0.5 mml, fixed 
in modified Karnovsky's fixative overnight, washed in 0.1 M cacodylate 
buffer, and post-fixed in 0.2% ruthenium tetroxide (RuO.) or 1 % osmium 
tetroxide, containing 0.5% potass ium ferrocyanide in 0.1 M cacodylate 
buffer for 30 min in the dark [4]. Ultrathin sections (60 -80 nm) were 
examined in a Zeiss lOA electron microscope. Statistical significances were 
detcrmjned using the Student t test. 
RESULTS 
Effects of One or Two Lipid Synthesis Inhibitors on Barrier 
Recovery Previous stud ies have demonstrated that 1) BCA is a 
potent inhibitor of epidermal serine-palmitoyl transferase [18], the 
rate-limiting enzyme for sphingolipid synthesis, 2) both lovastatin 
and fluvastatin are potent inhibitors of epidermal HMGCoA reduc-
tase [21,25,26]' the rate-limiting enzyme for cholesterol synthesis. 
Using these inhibitors alone and in combination provides another -
method to test the hypothesis that repair of barrier function requires 
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epidermal lipid synthesis. As seen in Table I, inhibition of either 
epidermal sphingolipid or cholesterol synthesis by topical applica-
tion of either of these inhibitors alone delayed barrier recovery in 
the acetone-treated model. In agreement with prior reports, inhibi-
tion of cholesterol synthesis delayed barrier recovery during the first 
6 h after application [21]. and BCA delayed recovery after 12 and up 
to 24 h [18J. When the two inhibitors were administered simulta-
neously, the rate of barrier recovery at early time points did not 
differ from animals treated with lovastatin alone; i.e., inhibition of 
sphingolipid synthesis did not affect the early stages of barrier re-
covery (Table I). Yet, whereas inhibition of spingolipid synthesis 
alone delayed the late phases of barrier recovery, simultaneous inhi-
bition of both sphingolipid and cholesterol synthesis paradoxically 
normalized the late phases of barrier recovery at both the 18- and 
24-h time points. These data show that simultaneous inhibition of 
both cholesterol and sphingolipid synthesis does not accentuate the 
early delay in barrier recovery and, paradoxically, improves recov-
ery rates at later time points. 
Effect ofInhibitor-Treatment on Lipid Content of Acetone-
Treated Stratum Corneum To explain the paradoxical nor-
malization of barrier function in the dual inhibitor-treated animals, 
we next examined the weight distribution of the key lipid species in 
stratum corneum 18 h after acetone treatment with or without 
added inhibitors. Acetone treatment followed by vehicle applica-
tions alone did not affect the free sterol, free fatty acid, or sphingoli-
pid content of the stratum corneum (Table II) . Likewise, fluvastatin 
treatment alone also did not affect stratum corneum lipid content at 
18 h. In contrast, BCA treatment, although not affecting sterol or 
free fatty acid levels, produced a significant decrease in total sphin-
golipids, including ceramides (Table II). Finally, in animals treated 
with both fluvastatin and BCA, the expected delay in barrier recov-
ery between 18 and 24 h did not occur (see above) . In these animals, 
the total sphingolipid and ceramide content of the stratum corneum 
was increased significantly in comparison to BCA-treated animals, 
ach ieving levels comparable to both control and vehicle-treated 
animals (Table II). These results agree with a previous report from 
this laboratory demonstrating that a BCA-induced defect in barrier 
function is associated with a decrease in sphingolipids in the stratum 
corneum [18] . Moreover, the simultaneous normalization of both 
barrier function and stratum corneum sphingolipid content in the 
animals treated with both BCA and fluvastatin further suggests that 
the defect in barrier function induced by BCA is due to a decrease in 
stratum corneum sphingolipids. The normalization of stratum cor-
neum sphingolipid content in BCA plus fluvastatin-treated animals 
may result from increased stimulation of de novo sphingolipid syn-
thesis that is induced by the decrease in early barrier recovery pro-
voked by the HMGCoA reductase inhibitors (sec DisClissiorl below). 
Electron Microscopy To gain insights into the mechanisms re-
sponsible for the paradoxical improvement in barrier function with 
dual inhibitor treatment, we compared epidermal ultrastructure in 
acetone-treated animals 18 h after application of veh icle or one or 
both inhibitors. As seen in Fig lC,D, both lamellar bodies and the 
resultant intercellular lamellar bilayers in the stratum corneum ap-
pear normal by 18 h after vehicle treatment, consistent with the 
= 75 - 80% return of barrier function to normal by this time point 
(Table I) [14 ,15,24]. In contrast, BCA, which causes a delay in 
barrier recovery at this time point (Table I) [18], produces distinc-
tive abnormalities in the lamellar body secretory system and inter-
cellular bilayer system (Fig lA,B). The secreted contents of lamellar 
bodies at the stratum granulosum-stratum corneum interface dis-
played clefts and lacunae of various sizes (Fig lA, asterisks). More-
over, lamel lar bilayers within the stratum corneum interstices 
lacked normal bilayer unit structure (Fig lB, versus 1 C) [4], instead 
appearing loosely packed and interspersed with electron-dense, 
amorphous material (Fig 1 C, double arrows) . However, treatment 
with HMGCoA reductase inhibitors, which causes a delay in the 
early stages of barrier recovery (Table 1, 5 - 6 h) [21,26]' results in 
normal-appearing lamellar bodies and intercellular bilayers at 18 h 
(Fig 2A,B), when barrier recovery rates are comparable to normal 
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Table I. Effects of C holesterol and Sphingolipid Synthesis Inhibito rs 
on Barrier Recovery in Acetone-Treated Animals' (% of Maximum TEWL) 
Time 
Group Inhibitor 5-6 Hours Sign ificance! 18 Hours Significance! 24 Hours Significance! 
1 
2 
3 
4 
Vehicle 
(n = 20) 
Fluvas tatin 
(n = 19) 
C hloroalaninc 
(n =20) 
Fluvastatin + chloroalanine 
(n = 28) 
• Data = Mean ± SEM. NS, not significant. 
• Versus ve hicle. 
69.7 ± 4.7 
82.6 ± 3.6 < 0.05 
64.5 ± 3.7 NS 
85. 1 ± 3.0 < 0.01 
(Table I). Finall y, th e normalization of barrier recovery ra tes by 
18 h that accompanies dual inhibitor treatment (Tabl e I) also is 
acco mpanied by normal-appearing lamellar bodies and intercellul ar 
bil ayers (Figs 2C-E). These results show that the paradoxical im-
provement in barrier function that accompanies dual inhibitor 
treatment can be attributed to normaliza tion of the lamellar body 
secretory system and its membrane products. 
Clinical Appearance and Barrier Function in Inhibitor-
Treated EFAD Mice Essentia l fatty acid deficient mouse skin is 
characterized by abnormal barrier function attributable to a defi-
ciency of the essential fatty acid , linoleic acid [27 ,28]. Moreover, the 
applications of linoleic ac id or related synthetic derivatives correct 
barrier function [1 9,28]. When EFAD mice were treated with vehi-
cle a lone for 0 to 8 d , the clinical appearance of the animals did not 
change (Fig 3V; untreated EFAD not shown). However, the scaling 
and erythema intensified in EFAD animals treated with either of the 
HMGCoA reductase inhibitors (Fi g 3 F). Moreover, both agents, 
prev iously show n to inhibit HMGCoA reductase activity in ace-
rone-treated and intac t skin [21,25,27], caused a further deteriora-
tio n in barrier function in the EFAD anima ls by day 4, which pro-
gress ively worsened thereafter (= fivefold increase by day 8; Table 
III, fluvastatin data not shown). In contrast, w hen EFAD animals 
were treated with topica l fJ-chl oro- L-a lanine, th e clinical appear-
ance of the animals improved (Fi g 1, BCA). Consistent with the 
clinical improvement, by day 6 a significant (= 50%), paradoxic 
improvement in TEWL occurred in comparison to vehicle-treated 
mice (Table III) , plateauing thereafter despite ongoing inhibitor 
applications. Because previous studies have demonstrated that fJ-
ch loro-L-al anine inhibits serine-palmi toyl transferase activity w hen 
35.7 ± 2. 1 23. 1 ± 3.0 
36.2 ± 4.6 N S 28. 1 ± 3.1 NS 
47 .9 ± 3.0 < 0.01 34.6 ± 2.1 < 0.01 
33.8 ± 3.3 NS 27.5 ± 3.0 NS 
applied to ace tone-treated, but not to intac t hairl ess mouse sk in [1 8] 
(data not shown), the lack of further improvements may refl ec t an 
inability of fJ-chloro-L-alanine to penetrate across th e stratum cor-
neum at sites were barrier function is largely res tored (i. e., 
TEWL ~ 1 Il1gjcm2j h) . 
Lipid Content of Inhibitor-Treated EFAD Epidermis T o 
ascertain th e biochemica l bas is for the paradoxical improvement in 
barrier function in EFAD animals treated with BCA, we next com-
pared the epidermal sphingolipid content of EFAD plus vehicle 
versus EFAD plus BC A-treated animals . Treatment of EFAD ani-
mal s with BCA resulted in a hi ghly significa nt decrease in the 
content of sphingolipids in EFAD epidermis (Tabl e IV). 
DISC USSION 
The permeability barrier function of mammalian kera tinizin g 
epithelia is regulated by a system of lipid-enriched, membrane bi-
layers in the intercellul ar spaces of stratum corneum (reviewed in 
[2]). Several studies have shown that the quantities of these lipids, 
rather than the number of cell layers o r thickness of the cornified 
layer, determine the permeability characteristics of a particular skin 
or mucosal site [7 ,24,29,30]. T he rol e of specific lipids in th e barrier 
remains incompletely understood. Of the mixture of lipids present 
in the stratum corneum of murine epidermis, it'llas now been shown 
that sphingolipids, cholestero l, and fatty ac ids are synth esized in 
response to barrier perturbations [14 ,15,17]. M oreover, because in-
hibitors of cholesterol and sphingolipid synth esis interfere with the 
recovery from acute barrier perturbations [1 8,2 1]' both of th ese 
lipids can be presumed to be important for permeability barrier 
homeostas is. T o tes t this hypothesis, we applied the HMGCoA 
Table II. Lipid Content of Stratum Corneum Following Inhibitor Treatment of Aceto ne-Trea ted Skin' 
Fraction 
Neutral Lipids 
Free Sterols 
Free Fatty Acids 
Total 
Sph ingolipids 
Ceramides 
Acylceramides 
Total 
• n =3. 
Normal 
6.09 ± 0.93 
7.39 ± 0.34 
13.48 ± 1.1 6 
20.00 ± 2.34 
2.71 ± 0. 53 
22.71 ± 2.87 
Lipid W eight % 
(Jlg/mg wet weight) 
Acetone + Acetone + 
Vehicle Fluvastatin 
6.53 ± 0 .40 6.00 ± 0.59 
9.63 ± 0.67 9.05 ± 0.80 
16.16 ± 0.58 15.05 ± 0.73 
19.73 ± 1.28 17.54 ± 2.40 
3. 16 ± 0. 59 2.95 ± 0.68 
22.89 ± 1.79 20.49 ± 3.08 
" Three separate animals in each group. Data represen t mean ± SEM. 
< Acetone + p-ch1oroalaninc versus vehicle - P < 0.05. 
• Acetone + p-chloroalaninc vs. vehicle - p < 0.05. 
Acctone + 
p-C hloroalan ine 
5.24 ± 1.1 9 
7.69 ± 1.70 
12.93 ± 1.37 
15.50 ± 1.08!·J 
2.30 ± 0.38 
17.81 ± 1.46',' 
Ace tone + Fluvastatin + 
p-Chloroalanine 
5.33 ± 0.13 
9.42 ± 1.40 
14.75 ± 1.26 
19.44 ± 0.87 
2.94 ± 0 .14 
22.38 ± 0.93/ 
~.J Acetone + p-chloro;d:m inc versus aceto ne + flu vastat in + p -chloroalaninc - p < 0.05. Other signifi cant differences include free sterols acetone + vchi clt~ versus acc-
tone + flu vastatin + p-chloroalaninc; p < 0.05); free fa try ac ids (normal versus vehicle; p < 0.05). 
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Figure 1. Ultrastructure of acetone-treated epidermis 18 h after either 
/1-chloroalanine (A , B; A + B) or velllcle (C, 0 ; A + V) treatment. /1-chlo r-
oa lanine treatment results in abnormal lamellar body (LB) contents (not 
shown; see [1 8]), and abnormal secreted contents at the stratum granulosum 
(SG) - stratum corneum (SC) interface (sil/gle arrows) w ith phase separation 
(a sterisks). Abnormal secreted LB contents result in both a paucity of in te r-
ce llular bilayers and abnormal bilayer structure and organization within the 
SC interstices (A, B, arrows). In contrast , by 18 h, vehicle-treated epidermis 
revea ls normal LB (0) , and normal numbers and structure of intercellul ar 
lamellar bilaye rs (C) . Ruthenium tetrox ide post-fi xation. A) bar, 1 tJ-m; 
B - 0) bar, 0.1 tim . 
reductase or· serine-palmitoyl transferase inhibitors singly or to-
geth er to either ace tone-treated or EFAD skin. W e hypothesized 
that deletion of an additional lipid should provoke a furth er deterio-
ration of barrier fun ction in the ace tone model. W e have shown 
here again that w hen Auvasta tin or BCA is a~plied alone tD acetone-
treated skin , t he early or later stages of barner recovery IS delayed, 
respectively [1 8,21). Utiliza tion of the two inh ibitors together did 
not, however, aggravate th e early delay induced by Auvastatin. This 
findin g is consistent with th ese and prior studies that demonstrated 
that BC A only inhibits barrier recovery after 6 h [18) . That this is 
not due to HMGCoA reductase inhibitors causing a max imal effect 
on barrier recovery is shown in recent studies where maximal inhi-
bition oHatty acid and chol es terol synthesis simultaneously resulted 
in a greater inhibition of barrier recovery than inhibition of either 
pathway alone [31] . 
A most unex pected findin g was the paradoxical improvement in 
barrier recovery at 18 and 24 h th at occurred with superimposition 
of Auvastatin on BC A treatment. This normalization is consistent 
w ith the changes in sphingolipid content induced by the inhibitors 
(Table II). Whereas BC A alone caused a decrease in stratum cor-
neum sphingolipid co ntent at this time [18), with th e d~al inhib.i-
tors sphingolipid content normalized by 18 h. Such an lIlcrease 111 
sphingo lipid content would correct th e proportIOn of choles terol, 
free fatty acid , and sphingolipids, presumabl y leadl11g to the forma-
tion of normal intercellular membrane bil ayers [32]. However, w hy 
sphingolipid content becomes normal in the face of th e dual inhibi-
tor treatment remains conjectural. One possibl e explanation might 
be th at the HMGCoA reductase inhibitor, by inhibiting barrier 
repair, stimulates sphingolipid synthesis (along with other lipids) to 
a greater degree than would occur with vehicle treatment alone. In' 
fact, prior studies have show n that topical applications of 
HMGCoA reductase inhibitors induced a global increase in lipid 
sy nth esis [25). This overall acceleration of lipid synthesis, in turn, 
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Figure 2. Ultrastructure of ace tone- trea ted epiderm is 18 h after either f1u-
vastatin (A, B; A + F) or f1u vastatin plus P-chloroalanine (C-E; A + F + B) 
treatment. With f1uvastatin treatment alone, the appearance of lamellar 
bodies (LB) wi thin the stratum granulosum (SG) cytosol appears normal (D, 
arrows; D , iI/set), as does the secreted contents of LB in the interce llular spaces 
(2B, sil/gle arrows). Moreover, normal intercellular bilaye rs are present within 
the intercellular spaces of the stratum corneum (SC) (A , double arrows). 
Treatment with both inhibito rs also yielded normal-appearing LB (D , E) 
and intercellular bilayers (C, dOIl/Jle arrows). This appearance was comparable 
to that observed w ith vehicle or fluvastatin alone (cf., Fi gs l C,D, and 2A,B, 
respectively), but distinctly di!fereIH from samples treated with p-chloroa-
lanine alone. Ruthenium tetroxide post-fi xa tion. Bar, 1 tim. 
would result in enhanced sphingolipid formation that could suffice 
to overcome the late BC A effect. This explanation also is consistent 
with previous studies that demonstrated that the increase in lipid 
synthesis that follows barrier disruption co rrelates directly with the 
extent of barrier perturbation [14,16). 
In th e seco nd approach , we applied each of the lipid synthesis 
B-CA v F 
Figure 3. C linica l appearance of essential fatty ac id defi cient hairless mice 
after one daily application of vehicle (V) , f1uvastatin (F) , o r /1-chloroalanine 
(B-CA) fo r 8 d. Note worsening of sca ling in F-trea ted animals, whereas the 
appearance of B-CA- trcated animals is improved. 
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Table Ill. Effects of Inhibitors on Barrier Function in Essential Fatty Acid Deficiency 
TEWL (mg/cm2/ h ± SEM) 
Time 
(Days) 
o 
2 
4 
6 
8 
/l-Chloroalanine 
(n =8) 
1.98±0.16 
1.25 ± 0.10 
1.50 ± 0.14 
1.00 ± 0.10 
1.05 ± 0.09 
Significance' 
NS 
NS 
NS 
< 0.01 
< 0.01 
• Significance of drug- versus vehicle-treated at same time point. NS, not significant. 
inhibitors to the skin of anima ls with a chronic barrier abnormality 
attributable to feeding an EFAD diet. Prior studies have demo n-
strated the specific requirement for linoleic ac id and its structural 
analogues in repairing the barrier [28,33,34]. Applications of 
HMGCoA reductase inhibitors caused a progressive worsening of 
the barrier (Table III) . This findin g was not surprisi ng, because 
EFAD is associated with accelerated choles terol synth esis, presum-
ably in an attempt to maintain barrier function [1 9]. T hus, th e 
fu rther deterioration in barrier function can be attributed to a dele-
tion of free sterols, superi mposed on the underlying defi ciency in 
essential fatty acids. Similarl y, occl usion of EFAD skin, which 
down-regulates chol es terol synth esis [19] , also leads to a further 
deterioration of barrier function in EFAD animals [20]. 
The explanation for the paradoxical improvement in barrier 
function that follows treatment with BCA is less apparent. It has 
been proposed that the molecular abnormali ty responsible for the 
barrier abnormality in EFAD is a specific substitutio n of non-essen-
tial fa tty acids (primarily oleate) for linoleate in the w-ester ified 
position of acy lsphingolipids [27]. On th e other hand , murine 
EFAD is accompanied both histochemically and ultrastructurally by 
a g lobal depletion of stratum corneum lipids [22], refl ected by a 
patchy loss of membrane bilayer structures in the intercellular spaces 
[4,22]. However, owing to the intense scaling in EFAD animals, it 
was not technically possible to isolate homogeneous sheets of stra-
tum corneum for biochemica l studies. Hence, it is still not known 
whether the quantities of sphingolipids are abnormal in EFAD stra-
tum corneum, either with or with out BCA treatment. N everthe-
less, prior studies have shown that the sy nthetic EFA, columbinic 
acid (C1 8: 3, n-3 trans), corrects the barrier abnormality in parallel 
to a selective, preferential pattern of incorporation into the W-ester-
ified position of acylceramides [33,34]. Moreover, we recently 
showed that columbinic acid can substitute fo r linoleic acid in the 
acute model of acetone-induced barrier disruption [32]. Hence, it 
seem s likely that a quali tative abnormality in acylceramides (oleate-
esterified acylsp hin golipids) does contribute to the ge nesis of the 
barrier abnormality in EFAD. One ca n hypothesize that BCA treat-
ment , which would decrease sphin golipid formation, would de-
crease the quantity of abnormal acylceramides that are thou ght to 
represent the mol ecul ar lesion in EFAD. Accordingly, BCA, by 
normalizing th e composition of the res idual lipids in EFAD stratum 
corneum, would paradoxically improve barrier function. 
Interestingly, despite ongoing topical applications of the inhibi-
Table IV. Epidermal Sphingolipid Content in fl- C hloroalanine 
versus Vehicle-Treated EFAD Animals" (n = 3) 
Lipid Weight (mg lipid/mg wet weight) 
EFAD + EFAD+ 
Fraction fJ-Chloroalanine Significance Vehicle 
Glycosphingoli pids 0.15 ± 0.01 < 0.05 0.25 ± 0.03 
Ceramides 0.81 ±0.1 3 < 0.05 1.63 ± 0.36 
Acylceramides 0.18 ± 0.04 <0.02 0.53 + 0.08 
Toral 1.1 4±0.16 < 0.05 2.41 ± 0.46 
.. Three separa te animals in eac h gro up; data represent mean ± SEM for each group. 
Vehicl e 
(n = 9) 
1.86 ± 0.22 
1.58 ± 0.24 
1.37±0.13 
1.79 ± 0.25 
1.77 ± 0.19 
Sign ificance' 
NS 
NS 
< 0.001 
< 0.01 
< 0.001 
Lovastatin 
(n = 8) 
1.44 ± 0.15 
1.33 ± 0.14 
3.26 ± 0.36 
3.07 ± 0.32 
6.22 ± 0.77 
tor, there was no further improvement in barrier fu nctio n beyond 
day 6 (Table III) . One explanation for this plateau effect may be the 
inability of BCA to penetrate intact skin; i.e., as the barrier im-
proves, the skin becomes progressively impervious to the inhibitor, 
a conclusion supported by the lack of inhibition of serine palmitoyl 
transferase fo llowing topical applications of BCA to intact skin 
(Mao-Qiang M , Holl eran WM, Feingold KR, Elias PM, unpub-
lished observations). 
These stud ie, are also consistent with th e hypothesis that a mix-
ture of th e key lipid species may be required for barrier homeostas is. 
T his concept derives from the synthesis studies cited above [re-
viewed in 31 j, and from three other observations . First, that topical 
applications of non-po lar solvents (petro leum ether) , which re-
moves only non-polar neutral lipids, leaving chol esterol and sphin-
golipids in place, causes only minor perturbations in the barrier [24] . 
In contrast, when a polar solvent (ace tone) is used, a progressive 
barrier deficiency occurs in proportion to the amount of lipid re-
moved, and this solvent, in contras t to petroleum ether, removes a 
represe ntative array of all three key lipid species [24] . Second, recent 
studies have demonstrated that suppl ying single or two-component 
mixtures of ceramides, choles terol, or free fa tty acids to acetone-
treated skin impedes barrier recovery [32]. In contrast, complete 
three-component mixtures do not interfere with normal barrier 
recovery. Lastly, insights have come from studies with lipid synthe-
sis inhibitors. When HMGCoA reductase or serine palmitoyl trans-
ferase inhibitors are applied to acetone-treated skin, they provoke a 
delay in barrier recovery that is attributable to inhibition of choles-
terol [2 1] and sp hingolipid [1 8] sy nth esis, respectively. These re-
sults, w hich have been confi rmed and extended here, are consistent 
with the requirement for an appropr iate mixture of all three key 
stratum corneum lipid fa milies: ceramides, free fatty acids, and cho-
lesterol. 
In summary, we have described the effects of lipid synthesis in-
hibitors, applied alone or together to acute ly or chronically per-
turbed skin . Deterioration or improvement in barrier function 
could be ascribed to both quantitative changes in total lipid as well as 
se lective depletion of individua l species resulti ng in alterations in 
th e proportions of the three key fa milies of stratum corneum lipids. 
These studies "aile beell supported by N IH gra uts A R 19098 alld 39639, as weI/ as 
the Medical Resea rci, Service, Velerall" Adlllill istra tioll. Ms. Sail)' Michael, Mr. Bil 
ClwpllwII (deceased), Mr. Paul Kretko/llski, alld Mr. Rayll/Glld Pelayo prollided 
excel/ell t editorial assistance. 
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ANNOUNCEMENT 
Western Retreat: Clinical Practice Update will be held Thursday through Saturday, August 
25 - 28, 1993, sponsored by Scripps Clinic and Research Foundation. 
This continuing medical education course is designed for physicians interested in updating 
their clinical knowledge on various specialty topics. The combination oflectures and discussion 
in a relaxed atmosphere will enhance the learning experience. This conference will be held at 
the beautiful new Skamania Lodge in the Columbia Gorge, in Stevenson, Washington. The 
Lodge is just 40 minutes from the Portland, Oregon International Airport. The course wi ll offer 
12 hours of Category I CME credit. 
For further information contact Department of Academic Affairs, 403C, Scripps C linic and 
Research Foundation , 10666 No. Torrey Pines Road, La Jolla, CA 92037. Telephone: (619) 
554-8556; FAX: (619) 554-6310. 
